FDA loosens marketing rules for authorized Covid drugs, but will it move the needle?
The FDA is changing up its marketing rules for emergency use Covid treatments. Six drugmakers can now more broadly promote their Covid therapies, including Pfizer’s Paxlovid and AstraZeneca’s Evusheld.
However, that doesn’t mean the companies are ready to roll out new ads. Pfizer and AstraZeneca declined comment, and a spokesperson for Eli Lilly — both baricitinib and bebtelovimab were included in the FDA memo — said in an email simply that “Lilly has and will continue to comply with all FDA rules regarding the advertising and promotion of EUA treatments.”
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 157,400+ biopharma pros reading Endpoints daily — and it's free.